Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Recursion Pharmaceuticals's gross margin for the twelve months ending Jun 30, 2026 was 3.5%. For fiscal 2025 it was 5.0%, against 23.1% the year before. The highest annual figure on record is 100.0% in fiscal 2020.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.0% | −18.1 |
| FY2024 | Dec 31, 2024 | 23.1% | +18.7 |
| FY2023 | Dec 31, 2023 | 4.5% | +25.6 |
| FY2022 | Dec 31, 2022 | -21.2% | −121.2 |
| FY2021 | Dec 31, 2021 | 100.0% | +0.0 |
| FY2020 | Dec 31, 2020 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -49.8% | −44.9 |
| Q1 FY2026 | Mar 31, 2026 | -93.0% | −44.9 |
| Q4 FY2025 | Dec 31, 2025 | 59.8% | +241.3 |
| Q3 FY2025 | Sep 30, 2025 | -183.8% | −237.5 |
| Q2 FY2025 | Jun 30, 2025 | -4.9% | −41.1 |
| Q1 FY2025 | Mar 31, 2025 | -48.0% | −67.1 |
| Q4 FY2024 | Dec 31, 2024 | -181.4% | −190.7 |
| Q3 FY2024 | Sep 30, 2024 | 53.7% | +57.0 |
| Q2 FY2024 | Jun 30, 2024 | 36.2% | +21.4 |
| Q1 FY2024 | Mar 31, 2024 | 19.1% | +21.6 |
| Q4 FY2023 | Dec 31, 2023 | 9.3% | −11.5 |
| Q3 FY2023 | Sep 30, 2023 | -3.3% | +13.8 |
| Q2 FY2023 | Jun 30, 2023 | 14.8% | +100.2 |
| Q1 FY2023 | Mar 31, 2023 | -2.6% | +43.7 |
| Q4 FY2022 | Dec 31, 2022 | 20.7% | −79.3 |
| Q3 FY2022 | Sep 30, 2022 | -17.1% | −117.1 |
| Q2 FY2022 | Jun 30, 2022 | -85.4% | −185.4 |
| Q1 FY2022 | Mar 31, 2022 | -46.2% | −146.2 |
| Q4 FY2021 | Dec 31, 2021 | 100.0% | – |
| Q3 FY2021 | Sep 30, 2021 | 100.0% | – |
| Q2 FY2021 | Jun 30, 2021 | 100.0% | – |
| Q1 FY2021 | Mar 31, 2021 | 100.0% | – |
See a number that looks wrong?